Table 2.
Distribution of Serologic Fibrosis Markers Depending on Demographic and Clinical Characteristics of Patients With NAA‐ALF
| Parameters | HA* | 4COL7S† | WFA+‐M2BP‡ | |
|---|---|---|---|---|
| (ng/mL) | (ng/mL) | (COI) | ||
| Sex | Male, n = 37 | 5,988 ± 8,973 | 17.9 ± 6.5 | 9.5 ± 4.8 |
| Female, n = 36 | 3,381 ± 5,612 | 15.6 ± 6.3 | 11.9 ± 5.2 | |
| Age of onset | ≥54, n = 27 | 6,462 ± 9,821 | 17.1 ± 6.1 | 11.2 ± 4.6 |
| <54, n = 46 | 3,815 ± 628 | 16.7 ± 6.8 | 10.4 ± 5.4 | |
| Etiology of ALF | Viral, n = 30 | 6,352 ± 9,578 | 15.7 ± 6.6 | 11.1 ± 4.6 |
| Nonviral, n = 43 | 3,680 ± 5,870 | 17.6 ± 6.4 | 10.5 ± 5.5 | |
| Etiology of ALF | Autoimmune, n = 22 | 3,317 ± 6,604 | 19.1 ± 5.7 | 12.5 ± 5.0|| |
| Nonautoimmune, n = 51 | 5,378 ± 8,030 | 15.9 ± 6.6 | 9.7 ± 4.9|| (0.04) | |
| KCC§ | Positive, n = 21 | 6,556 ± 9,072 | 20.9 ± 5.8¶ | 12.9 ± 4.9 |
| Negative, n = 52 | 3,853 ± 6,857 | 15.1 ± 6.0¶ (0.0005) | 10.0 ± 5.0 | |
| MELD | ≥24, n = 49 | 6,237 ± 8,749|| | 18.0 ± 6.7|| | 11.6 ± 5.3|| |
| <24, n = 24 | 1,530 ± 2,081|| (0.02) | 14.2 ± 5.3|| (0.03) | 8.9 ± 4.3|| (0.049) | |
| HE ≥grade 2 | None, n = 40 | 2,773 ± 5,476¶ | 14.5 ± 5.6¶ | 10.1 ± 5.1 |
| Acute, n = 12 | 7,711 ± 8,989¶ (0.006) | 18.1 ± 8.1 | 10.4 ± 3.8 | |
| Subacute, n = 21 | 6,628 ± 9,383 | 20.0 ± 5.5¶ (0.002) | 12.1 ± 5.8 | |
| Liver atrophy | None, n = 36 | 4,525 ± 8,335 | 14.3 ± 6.3¶ | 9.6 ± 5.5 |
| Atrophied, n = 37 | 4,979 ± 7,094 | 19.0 ± 5.8¶ (0.002) | 11.9 ± 4.5 |
Number of study subjects included: *64 cases; †66 cases; ‡60 cases. §KCC was assessed at admission. Data with statistical significance assessed by Kruskal–Wallis tests with significance in parentheses, || P < 0.05; ¶ P < 0.01.
Abbreviations: COI, cut‐off index; HE, hepatic encephalopathy.